Financial Engines Advisors L.L.C. Invests $222,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Engines Advisors L.L.C. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,401 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC lifted its position in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 in the last three months. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent analyst reports. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research note on Thursday, February 13th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Bank of America upped their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Price Performance

Shares of GILD stock opened at $111.79 on Friday. The stock’s fifty day simple moving average is $105.48 and its 200 day simple moving average is $94.81. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The firm has a market cap of $139.22 billion, a price-to-earnings ratio of 302.14, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date was Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.